John R. Horn, PharmD, FCCP and Philip D. Hansten, PharmD
References
1. Eberl S et al. Role of P-glycoprotein inhibition for drug interactions. Clin Pharmacokinet. 2007;46:1039-49.
2. Rengelshausen J et al. Contribution of increased oral bioavailability and reduced nonglomerular renal clearance of digoxin to the digoxin-clarithromycin interaction. Br J Clin Pharmacol. 2003;56:32-8.
3. Gurley BJ et al. Gauging the clinical significance of P-glycoprotein-mediated herb-drug interactions: comparative effects of St. JohnÕs wort, Echinacea, clarithromycin, and rifampin on digoxin pharmacokinetics. Mol Nutr Food Res. 2008;52:772-9.